Xsensio’s wearable chip that analyses proteins and hormones in real time draws €6 million

March 3, 2026 at 04:41 PM UTC
EU-Startups
Original: EN
Xsensio’s wearable chip that analyses proteins and hormones in real time draws €6 million

European health-tech innovation is accelerating, with Xsensio securing €6 million in Series A funding for its continuous biochemical monitoring chip. This investment, led by WI Harper, highlights growing investor confidence in real-time, data-driven healthcare solutions and Xsensio's potential to revolutionize patient monitoring. The funding signifies a crucial step towards integrating advanced biochemical data directly into clinical environments, offering unprecedented insights at the point of care. Xsensio's proprietary Lab-on-Skin technology features a modular, multi-sensor chip capable of analyzing biomarkers like proteins and hormones in interstitial fluid in real-time. Developed at EPFL, this platform is designed for scalable deployment and aims to provide clinicians with continuous biochemical data previously unavailable, enabling earlier detection of organ dysfunction in critical care, oncology, and post-surgical recovery. This innovation aligns with a broader European trend towards developing accessible and cost-effective semiconductor technology for health applications. The funding round places Xsensio within a robust European ecosystem of wearable health monitoring startups. The sector has seen over €42 million invested in 2025 and early 2026, with companies like Sava Technologies, Level Zero Health, Liom, and Ahead Health also raising significant capital for their respective advancements. This collective investment underscores Europe's commitment to fostering digital sovereignty in advanced healthcare technologies and enhancing personalized, preventive medicine.

Curated and translated by Europe Digital for our multilingual European audience.

Source Information

Publication: EU-Startups
Published: March 3, 2026 at 04:41 PM UTC
All rights remain with the original publisher.